   Signature [CONTACT_66726]-IQ 2.0 Feasibility Study #2: Use of Control-IQ Technology 2.0 in Adults, Children, and Preschoolers with Type 1 Diabetes Protocol Identifying Number: TP-0011713 IDE Number: G220181 IDE Sponsor: Tandem Diabetes Care, Inc. Version Number: v 3.0 20 SEP 2022 Medical Monitor and Protocol Chair Name, degree Title Jordan Pi[INVESTIGATOR_3388], MD Vice President & Medical Director, Tandem Diabetes Care Signature/Date Sponsor Representative Name, degree Title Ravid Sasson-Katchalski, PhD Director, Clinical Affairs, Tandem Diabetes Care Signature/Date 
B1Ravid KatchalskiDigitally signed by [CONTACT_66690]: 2022.09.26 15:03:32 -07'00'Jordan Pi[INVESTIGATOR_66673]: 2022.09.26 15:22:15 -07'00'

 
  Protocol Revision History Version Number Amendment Date Brief Description of Changes 1.0 16 MAY 2022 Initial Version Submitted to FDA 2.0 27 JUL 2022 Initial Version Approved by [CONTACT_8415] 3.0 20 SEP 2022 Updated for consistency between sections and figures: • Study schematic figure updated to note Sleep Activity is required • Synopsis and Section 3.[ADDRESS_72777] to match tables • Section 2.3.1 and 3.3: Clarified pregnancy test is for females “of childbearing potential” • Section 3.3: Clarified target is 112.5 mg/dL to be consistent with rest of protocol • Section 3.:4 Corrected visit numbers 10 and 14, and updated reference to section 3.4.1 Section 6.24: Clarified when a hyperglycemia/ketotic event qualifies as an AE, or as a SAE, an adverse event form should be completed.   
B2

 
   TABLE OF CONTENTS SITE PRINCIPAL INVESTIGATOR [INVESTIGATOR_66674] .............................................................. 8 CHAPTER 1: BACKGROUND INFORMATION .............................................................................................. 15 1.1 Introduction ........................................................................................................................................ 15 1.1.1 Disease Background ..................................................................................................................... 15 1.1.2 Tandem X2 Insulin Pump with Control-IQ Technology ............................................................. 15 1.2 Rationale ............................................................................................................................................. 15 1.3 Potential Risks and Benefits ............................................................................................................... 15 1.3.1 Known Potential Risks ................................................................................................................. 16 [IP_ADDRESS] Blood Draw .......................................................................................................................... 16 [IP_ADDRESS] CGM and Pump Catheter Risks ........................................................................................... 16 [IP_ADDRESS] Hypoglycemia ...................................................................................................................... 16 [IP_ADDRESS] Risk of Hyperglycemia ........................................................................................................ 16 [IP_ADDRESS] Risk of Device Reuse ........................................................................................................... 16 [IP_ADDRESS] Potential Risks of the CLC System ..................................................................................... 16 [IP_ADDRESS] Other Risks .......................................................................................................................... 17 1.3.2 Benefits ........................................................................................................................................ 17 1.3.3 Risk Assessment ........................................................................................................................... 17 1.4 General Considerations ...................................................................................................................... 17 CHAPTER 2: STUDY ENROLLMENT AND LEAD-IN PERIOD ...................................................................... 18 2.1 Participant Recruitment and Enrollment ............................................................................................ 18 2.1.1 Informed Consent and Authorization Procedures ........................................................................ 18 2.2 Participant Eligibility Criteria ............................................................................................................ 19 2.2.1 Inclusion Criteria .......................................................................................................................... 19 2.2.2 Exclusion Criteria ......................................................................................................................... 19 2.3 Visit 1: Screening Visit ...................................................................................................................... 20 2.3.1 Data Collection and Testing ......................................................................................................... 20 2.4 Screen Failures ................................................................................................................................... 21 CHAPTER 3: DEVICE TRAINING AND STUDY VISITS ................................................................................ 22 3.1 Visit 2: Control-IQ 1.5 Training Visit ................................................................................................ 22 3.1.1 Training on System Use ............................................................................................................... 22 3.1.2 Training on Management of Hypoglycemia ................................................................................ 23 3.1.3 Training on Management of Hyperglycemia ............................................................................... 23 3.2 Visits 3, 4 and 5: Control-IQ 1.5 follow up contacts ......................................................................... 24 B3

 
  3.3 Visit 6: Control-IQ 2.0 Training Visit ................................................................................................ 24 3.4 Study Contacts in the Treatment Period with Control-IQ 2.0 Technology ........................................ 25 3.4.1 Procedures at all Study Visits ...................................................................................................... 26 3.5 Unscheduled Visits ............................................................................................................................. 27 3.6 Late Bolus Meal Challenges............................................................................................................... 27 3.7 Adjustments in Insulin Pump Settings ............................................................................................... 27 3.8 Early Discontinuation of Study Device .............................................................................................. 27 3.9 Remote Monitoring ............................................................................................................................ 27 CHAPTER 4: STUDY DEVICES AND DRUGS ................................................................................................ 28 4.1 Study Devices ..................................................................................................................................... 28 4.1.1 Insulin Pump ................................................................................................................................ 28 4.1.2 Continuous Glucose Monitoring .................................................................................................. 28 4.1.3 Blood Glucose Meter ................................................................................................................... 28 4.1.4 Ketone Meter ................................................................................................................................ 28 4.2 Study Device and Drug Accountability Procedures ........................................................................... 28 4.3 Participant Access to Study Device at Study Closure ........................................................................ 28 CHAPTER 5: TESTING PROCEDURES AND QUESTIONNAIRES .................................................................. 29 5.1 General Challenge Guidelines ............................................................................................................ 29 5.1.1 Late Bolus Meal Challenges ........................................................................................................ 29 5.2 Laboratory Testing ............................................................................................................................. 30 5.2.1 HbA1c .......................................................................................................................................... 30 5.2.2 Urine Pregnancy ........................................................................................................................... 30 5.2.3 Patient Reported Outcomes .......................................................................................................... 30 CHAPTER 6: UNANTICIPATED PROBLEM, ADVERSE EVENT, AND DEVICE ISSUE REPORTING ............. 32 6.1 Unanticipated Problems ..................................................................................................................... 32 6.2 Adverse Events ................................................................................................................................... 32 6.2.1 Definitions .................................................................................................................................... 32 6.2.2 Reportable Adverse Events .......................................................................................................... 33 6.2.3 Hypoglycemic Events .................................................................................................................. 34 6.2.4 Hyperglycemic/Ketotic Events .................................................................................................... 34 6.2.5 Relationship of Adverse Event to Study Investigational Device ................................................. 35 6.2.6 Severity (Intensity) of Adverse Events ........................................................................................ 35 6.2.7 Expectedness ................................................................................................................................ 36 6.2.8 Coding of Adverse Events ........................................................................................................... 36 6.2.9 Outcome of Adverse Events ......................................................................................................... 36 B4

 
    6.3 Reportable Device Issues ................................................................................................................... 36 6.4 Timing of Event Reporting................................................................................................................. 37 6.5 Safety Oversight ................................................................................................................................. 37 6.6 Stoppi[INVESTIGATOR_2121] ................................................................................................................................ 38 6.6.1 Participant Discontinuation of Study Device ............................................................................... 38 6.6.2 Criteria for Suspending or Stoppi[INVESTIGATOR_3396] ..................................................................... 38 CHAPTER 7: MISCELLANEOUS CONSIDERATIONS ................................................................................... 39 7.1 Drugs Used as Part of the Protocol .................................................................................................... 39 7.2 Collection of Medical Conditions and Medications ........................................................................... 39 7.3 Prohibited Medications, Devices, Treatments, and Procedures ......................................................... 39 7.4 Rescue Medications, Treatments, and Procedures ............................................................................. 39 7.5 Pregnancy Reporting .......................................................................................................................... 39 7.6 Participant Compensation................................................................................................................... 39 7.7 Participant Withdrawal ....................................................................................................................... 39 CHAPTER 8: STATISTICAL CONSIDERATIONS .......................................................................................... 40 8.1 General Statistical Considerations...................................................................................................... 40 8.2 Statistical Hypotheses......................................................................................................................... 40 8.3 Sample Size ........................................................................................................................................ 40 8.4 Outcome Measures ............................................................................................................................. 40 8.5 Analysis Datasets ............................................................................................................................... 41 8.6 Analysis of Endpoints ........................................................................................................................ 41 8.6.1 Analysis of the Safety Event Endpoints ....................................................................................... 41 8.6.2 Analysis of Other Safety Endpoints ............................................................................................. 42 8.6.3 Analysis of CGM Endpoints ........................................................................................................ 42 8.6.4 Analysis of Late Bolus Meal Challenges ..................................................................................... 42 [IP_ADDRESS] Late Bolus Meal Challenge Safety and CGM Subgroup Analysis ...................................... 42 [IP_ADDRESS] Time to Intervention Analysis ............................................................................................. 43 [IP_ADDRESS] Number of interventions analysis ........................................................................................ 43 8.7 Intervention Adherence ...................................................................................................................... 43 8.8 Protocol Adherence and Retention ..................................................................................................... 44 8.9 Baseline Descriptive Statistics ........................................................................................................... 44 8.10 Additional Tabulations and Analyses............................................................................................... 44 8.11 Device Issues .................................................................................................................................... 44 8.12 Planned Interim Analyses ................................................................................................................. 44 8.13 Subgroup Analyses ........................................................................................................................... 45 8.14 Multiple Comparison/Multiplicity ................................................................................................... 45 B5

 
   8.15 Handling of Missing Data ................................................................................................................ 45 8.16 General Statistical Considerations.................................................................................................... 45 CHAPTER 9: DATA COLLECTION AND MONITORING............................................................................... 46 9.1 Case Report Forms and Other Data Collection .................................................................................. 46 9.2 Study Records Retention .................................................................................................................... 46 9.3 Quality Assurance and Monitoring .................................................................................................... 46 9.4 Protocol Deviations ............................................................................................................................ 47 CHAPTER 10: ETHICS/PROTECTION OF HUMAN PARTICIPANTS ............................................................ [ADDRESS_72778] ............................................................................................................................... 48 10.2 Institutional Review Boards ............................................................................................................. 48 10.3 Informed Consent Process ................................................................................................................ 48 10.3.1 Consent Procedures and Documentation ................................................................................... 48 10.3.2 Participant and Data Confidentiality .......................................................................................... 48 10.3.3 Future Use of Stored Specimens and Data ................................................................................. 49 CHAPTER 11: REFERENCES ....................................................................................................................... [ADDRESS_72779] Diabetes Control & Complications Trial DKA Diabetic Ketoacidosis eCRF Electronic Case Report Form FDA Food and Drug Administration GCP Good Clinical Practice HbA1c Hemoglobin A1c ICF Informed consent form ICH International Conference of Harmonisation IDE  Investigational Device Exemption IRB Institutional Review Board RBM Risk-Based Monitoring SAE Serious Adverse Event T1D Type [ADDRESS_72780]  
B7

 
   Site Principal Investigator [INVESTIGATOR_66675]: TP-0011713 Protocol Name: [CONTACT_66727]-IQ 2.0 Feasibility Study #2: Use of Control-IQ Technology 2.0 in Adults, Children, and Preschoolers with Type 1 Diabetes Protocol Version / Date: 3.0 / 20 SEP 2022  The Principal Investigators (undersigned) hereby [CONTACT_66691]. This trial will be carried out in accordance with the principles of Good Clinical Practice (GCP) and as required by [CONTACT_716], as applicable: [LOCATION_002] (US) Code of Federal Regulations (CFR) (45 CFR Part 46, 21 CFR Part 50, 21 CFR Part 56, 21 CFR Part 312, and/or 21 CFR Part 812). By [CONTACT_66692], the investigators agree to the above and to fully co-operate with all monitoring and audits in relation to this trial by [CONTACT_66693], including source data, by [CONTACT_66694], Inc., IRBs and/or by [CONTACT_66695], State and local regulatory authorities.  Investigator Name: ___________________________________________  Investigator Signature: ________________________________________  Date (DD/MMM/YYYY): ______________________________________  
B8

 
 PROTOCOL SUMMARY Study Sponsor Tandem Diabetes Care, Inc. Protocol Number TP-0011713 Protocol Title Control-IQ 2.0 Feasibility Study #2: Use of Control-IQ Technology 2.0 in Adults, Children, and Preschoolers with Type 1 Diabetes Précis This feasibility study is a prospective, randomized, two-period crossover multi-center study of 2 weeks of home use of Control-IQ 1.5 technology (run-in period), followed by 2 weeks of home use of Control-IQ 2.0 technology at one target, followed by 2 weeks of home use of Control-IQ 2.0 at another target. This automated insulin dosing (AID) system will be evaluated in multiple age groups, with late bolus meal challenges. Products t:slim X2 insulin pump with Control-IQ technology 1.5 (Run-In Period) t:slim X2 insulin pump with Control-IQ technology 2.0 (Treatment Periods) Objectives The objectives of the study are to assess safety of and explore glycemic outcomes with Control-IQ technology 2.[ADDRESS_72781] 72 complete the study (at least 30 participants age 14+, at least [ADDRESS_72782] 12 participants age 2-5), plus local contacts for adult participants.  Enrollment goal is at least 50% of all participants in each age group have an HbA1c at baseline of ≥ 7.5%.                                                                                                                             Participant Population: Eligibility to enroll in the study will be assessed based on the following inclusion criteria: 1. Age 2 to ≤ [ADDRESS_72783] 11 of the prior 14 days of CGM use available for download at the screening visit to confirm eligibility 4. Total Daily Insulin Dose (TDD) at least 2 units/day 5. Weight ≥ 20 lbs 6. HbA1c ≤ 10.5% 7. For participants <18 years old, living with one or more parent/legal guardian knowledgeable about emergency procedures for severe hypoglycemia, present with the participant during and for 5 hours (3 hours for participants age 2-5) after the meal challenges, and willing to use the Dexcom Follow app (with push notifications turned on) for the duration of the study.  8. For participants ≥[ADDRESS_72784] during the late bolus meal challenges, agrees to be promptly available if contact[CONTACT_66696], and willing to use the Dexcom Follow app (with push notifications turned on) for the duration of the study. If the participant lives alone, the local contact [CONTACT_66697] [ADDRESS_72785] overnight.  9. Investigator has confidence that the participant and/or parent/guardian can successfully operate all study devices and is capable of adhering to the protocol. 10. Willing to use only aspart (novolog) or lispro (humalog) insulin with the study devices, with no use of long-acting basal insulin injections, or inhaled insulin with the study devices. 11. Have current glucagon product to treat severe hypoglycemia (injectable or nasal) at home (site will provide prescription if they do not have one) B9

 
 12. Willing and able to perform the study late bolus meal challenges. Eligibility to enroll in the study will be assessed based on the following exclusion criteria:  1. More than 1 epi[INVESTIGATOR_66676] (DKA) in the past 6 months 2. More than 1 epi[INVESTIGATOR_66677] (needing assistance) in the past [ADDRESS_72786] 6 months  4. For Female: Currently pregnant or planning to become pregnant during the time period of study participation a. A negative pregnancy test will be required for all females of child-bearing potential b. Counseling on appropriate birth control options will be provided to all females of child-bearing potential 5. Concurrent use of any non-insulin glucose-lowering agent, other than metformin (for example, GLP-1 agonists, Symlin, DPP-4 inhibitors, SGLT-2 inhibitors, sulfonylureas). 6. Hemophilia or any other bleeding disorder 7. Hemoglobinopathy 8. History of heart, liver, lung or kidney disease determined by [CONTACT_66698] 9. History of allergic reaction to Humalog or Novolog 10. Use of any medications determined by [CONTACT_66699] 11. Significant chronic kidney disease (which could impact CGM accuracy in investigator’s judgment) or hemodialysis 12. Concurrent use of any medication that could interfere with the study CGM, such as hydroxyurea 13. History of adrenal insufficiency 14. History of abnormal TSH consistent with hypothyroidism or hyperthyroidism that is not appropriately treated 15. History of gastroparesis 16. A condition, which in the opi[INVESTIGATOR_66678], would put the participant or study at risk 17. Participation in another pharmaceutical or device trial at the time of enrollment or anticipated for during the time period of study participation 18. Employed by, or having immediate family members employed by [CONTACT_3438], Inc., or having a direct supervisor at place of employment who is also directly involved in conducting the clinical trial (as a study investigator, coordinator, etc.); or having a first-degree relative who is directly involved in conducting the clinical trial                                                      Participant Duration Approximately 6-[ADDRESS_72787] target, and treatment period with Control-IQ technology 2.0 at the lower target, where the order of treatment periods will be randomized. Primary Endpoints: 1. Severe hypoglycemia (with cognitive impairment such that assistance of another individual is needed for treatment) during study compared with data on severe hypoglycemic events reported by T1D Exchange clinic registry over a 3-month time period 2. Diabetic ketoacidosis during study compared with data on DKA events reported by T1D Exchange clinic registry over a 3-month time period 3. Number of unanticipated adverse device effects 4. Number of other serious device-related adverse events Secondary Endpoints: 1. All device-related adverse events 2. CGM hypoglycemia outcomes, compared between the three study time periods  a. Overall % time <54 mg/dL b. Overall % time <70 mg/dL 3. Times in ranges-overall (70-180 mg/dL, >180 mg/dL, >250 mg/dL, 70-140 mg/dL) compared between the three study time periods 4. Mean glucose compared between the three study time periods 5. Overall variability (CV and SD) compared between the three study time periods 6. Secondary endpoints 2 – 5 compared during daytime and nighttime, across the three study time periods  7. Secondary endpoints 2 - 5 as well as adverse events, during the study meal challenge periods, for late bolus feature use compared to normal bolus in the meal challenges. 8. Time to intervention for hypo- or hyperglycemia during the study meal challenge periods, for late bolus feature use compared to normal bolus in the meal challenges. 9. Number of interventions for hypo- or hyperglycemia during the study meal challenge periods for late bolus feature use compared to normal bolus in the meal challenges. 10. Subgroup Analysis for all metrics by [CONTACT_50802], baseline HbA1c cohort, and target activity use (standard target, lower target, sleep activity, exercise activity) Protocol Overview/Synopsis After consent is signed, eligibility will be assessed.   Run-In Period: Participants will return to clinic to undergo device training with the study CGM and a Control-IQ technology 1.[ADDRESS_72788] a phone follow up phone call at 1 day, 3 days and 1 week after starting Control-IQ technology 1.5 use, and will return to clinic at two weeks to commence Control-IQ technology 2.0 training.  Treatment Periods: Participants will then use the study pump with Control-IQ technology 2.0 for 4 weeks during the study period (2 weeks with a lower target of 90-130 mg/dL, and [ADDRESS_72789] target of 112.5-160 mg/dL, in random order). Participants will have a follow up contact [INVESTIGATOR_136] [ADDRESS_72790] 3 days later and 1 week after switching targets, and a follow up visit at 4 weeks to end the study. Participants will use the t:slim X2 insulin pump with Control-IQ technology 2.0 turned on. It is acceptable to use manual mode when there is a loss of CGM data. Each participant will perform 2 late bolus meal challenges in each two-week period, contact[CONTACT_66700]. An assessment of adverse events, using open ended questions to capture hyperglycemic and hypoglycemic events, and their underlying cause and relationship to the study device or other parts of the system (such as the infusion set), will occur at all visits/contacts. Study Safety Plan:  Participants will be given a blood glucose and ketone meter to use throughout the study, and will be trained on their use by [CONTACT_3436].  BGM readings will be performed in accordance with the participant instruction sheet and per CGM manufacturer instructions. Ketone readings will be performed per the participant instruction sheet. Site investigators may adjust insulin delivery profile settings as needed throughout the study in accordance with their clinical practice. Real-time CGM alerts will be sent to study staff providers (MD, DO, NP, PA) for the first ten 6-13 year old participants to begin use of the lower target (90-130 mg/dL) for the first week of Control-IQ 2.0 use at that target. In addition, real-time CGM alerts will be sent to study staff providers for all 2-5 year old participants throughout their use of Control-IQ 2.0 technology (all 4 weeks).  
B12

 
SCHEMATIC OF STUDY DESIGN  
B13

 
SCHEDULE OF STUDY VISITS AND PROCEDURES 
1Late meal bolus challenges will occur throughout Control-IQ 2.[ADDRESS_72791] at Control-IQ 1.5 device training does not need to be repeated if screening and Control-IQ 1.5 training visits are performed on the same day. Visit Number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 UV   Run-In Period Treatment Period  Screening Visit Control-IQ 1.5 Training Visit Control-IQ 1.5 Run-In Period Control-IQ 2.0 Training Control-IQ 2.0 Treatment Period 1 Control-IQ 2.0 Treatment Period 2    Up to 2 weeks after screening 1d 3d 1w 2w 1d 3d 1w 2w 1d 3d 1w 2w (Final  Visit) UV Visit (V) or Contact (C) V V C C C V C C C V C C C V V/C Informed Consent X               Eligibility Assessment X               Medical history/ physical exam X               Height, weight, blood pressure and pulse X               HbAlc (POC or local lab) X               Pregnancy test (females of child-bearing potential) X X2    X          Questionnaires      X    X    X  Assessment of Device Use X     X          Study system training  X    X    X      Late Meal Bolus Challenges1        X  X  AE/Device Issue Assessment   X X X X X X X X X X X X X Upload and Review Study Device Data   X X X X X X X X X X X X X 
B14

 
Chapter 1: Background Information 1 1.1 Introduction 2 1.1.1 Disease Background 3 Type 1 diabetes affects 1.25 million people in the [LOCATION_002]. Approximately 70% of individuals with 4 type 1 diabetes report poor metabolic control, and do not meet the American Diabetes Association’s 5 recommended goal of hemoglobin A1c (HbA1c) level of 7.0%. These findings indicate the need for better 6 approaches to type 1 diabetes management. 7 1.1.2 Tandem X2 Insulin Pump with Control-IQ Technology 8 The Tandem X2 insulin pump with Control-IQ technology is an FDA-approved closed-loop control 9 (CLC) system based on the control algorithm developed and initially tested in the University of 10 Virginia’s DiAs system and then implemented in the inControl system (TypeZero, Technologies, Inc.). 11 Use of the Control-IQ system has been extensively tested in adults and children with type 1 diabetes 12 (T1D), demonstrating its efficacy and safety when used with insulin lispro (Humalog) or insulin aspart 13 (Novolog).1,2 The system is currently approved for ages 6 years and older and its use in younger children 14 is currently being studied (clinical trials.gov [STUDY_ID_REMOVED]). There are over 150,000 users of the 15 system since it became commercially available in 2020. A recent evaluation of real-world use of the 16 system in 9,451 users age >[ADDRESS_72792] usability improvements and other enhancements 20 intended to further reduce risk. The Control-IQ 1.5 system also allows for a wider range of inputs to 21 weight and total daily insulin, allowing it to be used by a broader group of individuals with diabetes, and 22 has been evaluated in numerous clinical trials ([STUDY_ID_REMOVED], [STUDY_ID_REMOVED], [STUDY_ID_REMOVED]). 23 Control-IQ technology 2.0 incorporates all the changes in version 1.5, and adds several new features 24 intended to improve time-in-range with no significant increase in hypoglycemia. These changes also 25 include features to improve safety around exercise, and to make bolusing for meals safer. Control-IQ 26 technology 2.0 was recently studied in 30 adults and adolescents age 14+, with over 20,000 hours of use, 27 and showed improvements in time in range without increases in hypoglycemia ([STUDY_ID_REMOVED]).  28 1.2 Rationale 29 The objective of this randomized, prospective, two-period crossover study conducted in three age cohorts 30 is to assess safety and explore glycemic outcomes associated with use of Control-IQ technology 2.0 31 including Adults and Adolescents age 14+ years old, children age 6-13 years old, and preschool children 32 age 2-5 years old. Participants will evaluate Control-IQ 2.0 technology using different glycemic targets, 33 as well as perform late bolus meal challenges.  34 1.3 Potential Risks and Benefits 35 Risks and Benefits are detailed below. Loss of confidentiality is a potential risk; however, data are 36 handled to minimize this risk. Hypoglycemia, hyperglycemia and ketone formation are always a risk in 37 participants with type 1 diabetes and participants will be monitored for these events. 38 
B15

 
1.3.1 Known Potential Risks 39 [IP_ADDRESS] Blood Draw 40 A venipuncture and/or fingerstick will be performed to obtain blood for HbA1c measurement. [ADDRESS_72793] for 45 several weeks. The risk of local infection is less than 1 in 1000 with either venipuncture or fingerstick. 46 [IP_ADDRESS] CGM and Pump Catheter Risks 47 There is a small risk of bleeding where the sensor or infusion set is inserted. There is a small risk for 48 developi[INVESTIGATOR_007] a local skin infection at the site of CGM sensor placement of pump infusion set placement. 49 This may be associated with swelling, redness and pain; and may require antibiotic therapy. Rarely, a [ADDRESS_72794] a small portion of the sensor under the skin that may cause redness, 51 swelling or pain at the insertion site. 52 Some participants may develop skin irritation or allergic reactions to the adhesives used to secure the 53 CGM, or to secure the insulin infusion sets for the continuous subcutaneous insulin infusion. If these 54 reactions occur, different adhesives or “under-tapi[INVESTIGATOR_007]” (such as with IV 3000, Tegaderm, etc.) will be 55 tried, sites will be rotated frequently, and a mild topi[INVESTIGATOR_66679] 56 required.  57 [IP_ADDRESS] Hypoglycemia 58 As with any person having type 1 diabetes and using insulin, there is always a risk of having 59 hypoglycemia. The frequency of hypoglycemia should be no more and possibly less than it would be 60 as part of daily living. Symptoms of hypoglycemia can include sweating, jitteriness, and not feeling well. 61 There is the possibility of fainting or seizures (convulsions) and that for a few days the participant may 62 not be as aware of symptoms of hypoglycemia. A CGM functioning poorly and significantly over-63 reading glucose values could lead to inappropriate insulin delivery. The study meal challenges, requiring 64 boluses to be delivered late, could increase the risk of hypoglycemia. 65 [IP_ADDRESS] Risk of Hyperglycemia 66 Hyperglycemia and ketonemia could occur if insulin delivery is attenuated or suspended for an 67 extended period or if the pump or infusion set is not working properly. A CGM functioning poorly 68 and significantly under-reading glucose values could lead to inappropriate suspension of insulin delivery. 69 The study meal challenges, requiring boluses to be delivered late, could increase the risk of 70 hyperglycemia. 71 [IP_ADDRESS] Risk of Device Reuse 72 All devices will be used by a single study participant only. There will be no device reuse. 73 [IP_ADDRESS] Potential Risks of the CLC System 74 Even though the study system has been tested prior to this study, there is still a risk that parts of the 75 system may not function properly. The following are possible reasons the system may deliver too much 76 insulin or incorrectly stop insulin delivery: 77 • CGM sensor reads higher or lower than the actual glucose level which increases risk for 78 hypoglycemia and hyperglycemia with automated insulin delivery system; 79 

 
 • Device malfunctions that could produce a suspension of insulin delivery or over delivery of insulin. 80 [IP_ADDRESS] Other Risks 81 Data downloaded from the CGM, pump, and the home glucose and ketone meter will be collected for the 82 study. The downloaded data from the participant’s home devices at the screening visit may include data [ADDRESS_72795] 2 weeks prior to screening. Some people may be uncomfortable with the 84 researchers' having such detailed information about their daily diabetes habits. 85 1.3.2 Benefits 86 Participants may achieve better glucose control than they are currently achieving using their home insulin 87 pump.  88 The individual participant may not benefit from study participation. 89 1.3.3 Risk Assessment 90 Based on the facts that (1) individuals with diabetes experience mild hypoglycemia and hyperglycemia 91 frequently as a consequence of the disease and its management, (2),  mitigations are in place, and have 92 been tested in prior studies using the investigational device system in the home setting, that limit the 93 likelihood of excessive insulin dosing or prolonged withdrawal of insulin, and (3) rapid reversal of [ADDRESS_72796] their origin in the 100 Declaration of Helsinki, with the protocol described herein, and with the standards of Good Clinical 101 Practice (GCP). [ADDRESS_72797] that the intervention is investigational. Therefore, an investigational device exemption (IDE) from the 104 U.S. Food and Drug Administration (FDA) is required to conduct the study. 105  106 
B17

 
Chapter 2: Study Enrollment and Lead-in Period [ADDRESS_72798] 72 complete 109 closed loop use (at least 30 participants age 14+, at least [ADDRESS_72799] 12 110 participants age 2-5), plus local contacts for adult participants. [ADDRESS_72800] ten 6-13 year olds who complete this 114 trial. Criteria to begin enrolling 2-5 years will include 1) No UADE’s affecting participant safety, 2) [ADDRESS_72801] not been met overall (total AE’s related to DKA or severe hypoglycemia), 116 3) No safety concerns from all parties and approval from all parties to continue the study. This review [ADDRESS_72802] 50% of all participants in each age group have an HbA1c at baseline 119 of ≥ 7.5%, and to have at least [ADDRESS_72803] the overall recruitment goal.          123 2.1.1 Informed Consent and Authorization Procedures 124 Potential eligibility may be assessed as part of a routine-care examination. Before completing any 125 procedures or collecting any data that are not part of usual care, written or electronic informed consent 126 will be obtained. 127 For potential study participants, the study protocol will be discussed with the potential study participant 128 by [CONTACT_464]. The potential study participant will be given the Informed Consent Form to read. Potential 129 study participants will be encouraged to discuss the study with family members and their personal 130 physicians(s) before deciding whether to participate in the study.  131 For participants less than 18 years of age, a parent/legal guardian will be provided with the Informed 132 Consent Form to read and will be given the opportunity to ask questions. Assent will be obtained from 133 subjects 7 to <18 years of age. A legally authorized representative (parent/guardian) must sign the consent 134 form for all participants less than 18 years of age, and agree to the CGM monitoring requirements of the 135 study. 136 A copy of the consent/assent form will be provided to the participant and if the participant is a minor, 137 his/her parent/guardian, and another copy will be added to the participant’s study record. 138 As part of the informed consent process, each participant will be asked to sign an authorization for 139 release of personal information. The investigator, or his or her designee, will review the study-specific 140 information that will be collected and to whom that information will be disclosed. After speaking with 141 the participant and/or parent/guardian, questions will be answered about the details regarding [ADDRESS_72804] is required for all participants > [ADDRESS_72805] meet all of the following inclusion criteria in order to be eligible to participate in the 149 study. 150 1. Age 2 to ≤ [ADDRESS_72806] 11 of the prior 14 days of CGM use available for 154 download at the screening visit to confirm eligibility 155 4. Total Daily Insulin Dose (TDD) at least 2 units/day 156 5. Weight ≥ 20 lbs 157 6. HbA1c < 10.5% 158 7. For participants <18 years old, living with one or more parent/legal guardian knowledgeable 159 about emergency procedures for severe hypoglycemia, present with the participant during and for 160 5 hours (3 hours for participants age 2-5) after the meal challenges, and willing to use the 161 Dexcom Follow app (with push notifications turned on) for the duration of the study. 162  163 8. For participants ≥[ADDRESS_72807] during the late bolus meal 165 challenges, agrees to be promptly available if contact[CONTACT_66696], and willing to use the 166 Dexcom Follow app (with push notifications turned on) for the duration of the study. If the [ADDRESS_72808] overnight.  169  170 9. Investigator has confidence that the participant and/or parent/guardian can successfully operate 171 all study devices and is capable of adhering to the protocol. 172 10. Willing to use only aspart (novolog) or lispro (humalog) insulin with the study devices, with no [ADDRESS_72809] to treat severe hypoglycemia (injectable or nasal) at home (will [ADDRESS_72810] one). 176 12. Willing and able to perform the study late bolus meal challenges. 177 2.2.2 Exclusion Criteria 178 Individuals meeting any of the following exclusion criteria at baseline will be excluded from study 179 participation. 180 1. More than 1 epi[INVESTIGATOR_66676] (DKA) in the past 6 months 181 2. More than 1 epi[INVESTIGATOR_66677] (needing assistance) in the past [ADDRESS_72811] 6 months 183 4. For Female: Currently pregnant or planning to become pregnant during the time period of study 184 participation 185 • A negative pregnancy test will be required for all females of child-bearing potential  186 B19

 
• Counseling on appropriate birth control options will be provided to all females of child-187 bearing potential 188 5. Concurrent use of any non-insulin glucose-lowering agent, other than metformin (for example, 189 GLP-1 agonists, Symlin, DPP-4 inhibitors, SGLT-2 inhibitors, sulfonylureas). 190 6. Hemophilia or any other bleeding disorder 191 7. Hemoglobinopathy 192 8. History of heart, liver, lung or kidney disease determined by [CONTACT_66701] 193 study 194 9. History of allergic reaction to Humalog or Novolog 195 10. Use of any medications determined by [CONTACT_66699] 196 11. Significant chronic kidney disease (which could impact CGM accuracy in investigator’s 197 judgment) or hemodialysis [ADDRESS_72812] of employment who is also directly involved in conducting the 209 clinical trial (as a study investigator, coordinator, etc.); or having a first-degree relative who is 210 directly involved in conducting the clinical trial 211 2.3 Visit 1: Screening Visit [ADDRESS_72813] physical exam (including vital signs and height and weight measurements) will be performed 217 by [CONTACT_3437] (a physician, fellow, nurse practitioner or a physician assistant). 218 Height, weight and vital signs may be recorded by [CONTACT_66702]. 219 The following procedures will be performed/data collected/eligibility criteria checked and documented: 220 • Inclusion and exclusion criteria assessed 221 • Demographics (age or year and month of birth for preschool participants, sex, race and ethnicity and 222 socioeconomic information ) 223 • Subject initials to verify eCRF entry is associated with the correct individual  224 B20

 
• Contact [CONTACT_3031] (retained at the site and not entered into study database) 225 • Medical history 226 • Concomitant medications 227 • Physical examination to include: 228  Weight, height 229  Vital signs including measurement of blood pressure and pulse 230 • Blood draw (venipuncture or fingerstick) for local HbA1c measurement 231 • Urine pregnancy test for all females of childbearing potential who are premenopausal and not 232 surgically sterile 233 • Current device download, to include insulin pump and CGM device data, for up to the last two weeks [ADDRESS_72814] occur in clinic and 236 cannot be performed remotely. 237 2.4 Screen Failures 238 Individuals who do not initially meet study eligibility requirements may be rescreened one more time at a 239 later date per investigator discretion. 240  241 
B21

 
Chapter 3: Device Training and Study Visits 242 3.1 Visit 2: Control-IQ 1.[ADDRESS_72815] for all females of childbearing potential (postmenarchal) who are premenopausal 251 and not surgically sterile will be completed. 252 Participants will receive supplies for blood glucose and ketone testing. Quality Control (QC) testing will 253 be performed on the meters before they are dispensed. 254 All participants will use study supplied Control-IQ technology 1.5 pumps during the study run-in phase, 255 even if they are current Control-IQ technology users. Pump settings may be transferred over from the 256 participant’s prior pump, or for current multiple daily injection users, can be started per the guidance on [ADDRESS_72816]. 258 3.1.1 Training on System Use 259 All participants will receive study system training from qualified staff, to include CGM and Control-IQ 260 training. 261 At a minimum training will include the following: 262 • Calibration of the CGM in accordance with manufacturer labeling 263 • Procedures for treating severe hypoglycemia 264 • Procedures for identifying potential infusion set failure and steps to take including the checking of the 265 blood ketone level and changing the infusion set 266 • Use of the security PIN on the insulin pump will be required for anyone who is not entirely [ADDRESS_72817] or office visit. 273 The participant will be instructed to use the system in closed-loop mode except 1) when no calibrated 274 CGM sensor is available or 2) if insulin is delivered by [CONTACT_3451] (e.g. 275 injection of subcutaneous insulin via syringe in the event of infusion site failure). If insulin is delivered 276 by [CONTACT_3451], participant will be instructed to turn off Control-IQ for the next 277 four hour and until CGM glucose is < 180 mg/dL. [ADDRESS_72818] study staff during periods of illness with an elevated 279 temperature >101.5 degrees Fahrenheit (38.6 degrees Celsius), periods of significant illness, or during [ADDRESS_72819]-party 292 components for this purpose. The t:connect mobile app from Tandem Diabetes Care will not be [ADDRESS_72820] is required as per the study visit schedule 295 and will make arrangements with the participant for the contacts.  296 Participants may complete the device training visit in more than 1 session if necessary. 297 3.1.2 Training on Management of Hypoglycemia 298 The t:slim X2 with Control-IQ system will issue a predictive hypoglycemia alert (Control-IQ Low Alert) 299 when the system predicts BG <70 mg/dL within the next 15 minutes (<80 mg/dL when exercise mode is 300 activated). Participants will be permitted to change the CGM low glucose threshold alert setting on their 301 device (or Dexcom mobile app), but will be instructed to choose a value no less than 70 mg/dL. 302 If the participant receives a Control-IQ Low Alert, a message appears on the user interface that is 303 accompanied by [CONTACT_66703]/or sound if not acknowledged by [CONTACT_30799] [ADDRESS_72821] blood glucose and treat with carbohydrate. 306 The participant (and /or parent/guardian) will be instructed that if severe hypoglycemia occurs, the study 307 pump’s insulin delivery should be suspended and glucagon administered if the participant is unable to [ADDRESS_72822] one will be given a prescription for the glucagon emergency kit. 311 3.1.3 Training on Management of Hyperglycemia 312 The t:slim X2 with Control-IQ system will issue a predictive hyperglycemia alert (Control-IQ High Alert) 313 when the system has increased insulin delivery, but detects a CGM value above 200 mg/dL and does not [ADDRESS_72823] the value will decrease in the next 30 minutes. During the course of the study, participants will be 315 permitted to change the CGM high glucose threshold alert setting on their device or mobile app, but will 316 be instructed to choose a value no greater than 300 mg/dL. [ADDRESS_72824] blood glucose. 319 If a participant’s CGM reading is >300 mg/dL for more than 60 minutes or is ≥400 mg/dL at any point, 320 the participant will be instructed to take the following steps: 321 • Perform a blood glucose meter check. 322 • If the blood glucose is >300 mg/dL, check for blood ketones with the study ketone meter. 323 
B23

 
• If the ketone level is ≥ 0.6 mmol/L (or ≥ 2.5 mmol\L at any time), take correction insulin, change 324 insulin (pump) infusion site and contact [CONTACT_464]. Continue to monitor their glucose and blood 325 ketone levels until they return to normoglycemia and ketones are < 0.6 mmol/l. 326  If ketones are <0.6 mmol/l, participants will be advised to continue to monitor their glucose 327 until it returns to normoglycemia and to repeat the ketone measurement in 90 minutes if 328 necessary 329 • If correction insulin is administered via insulin syringe, turn Control-IQ off for four hours and until 330 glucose level has returned to <180 mg/dL. 331 3.2 Visits 3, 4 and 5: Control-IQ 1.5 follow up contacts 332 Following the Control-IQ 1.5 Training Visit, participants will use the study Control-IQ 1.5 pump and 333 study CGM for ~[ADDRESS_72825] will occur at 1 day (+12 hours), 3 334 days (1 day) to review adverse events as well as discuss infusion set care, and another phone call at 7 335 days (2 days). Participants will then return to clinic in approximately 2 weeks (3 days). 336 3.3 Visit 6: Control-IQ 2.[ADDRESS_72826] and exercise activity. The late bolus feature will also be available. 341 Participants will be randomized to use either a daytime 30-min predictive glucose target of 90-130 mg/dL 342 or 112.5 to 160 mg/dL for the first two-week period, then switch to the other target after 2 weeks.  343 In the training visit, participants will: 344 1) Select the appropriate target in clinic on their study pump per the randomization, and will be 345 instructed by [CONTACT_66704].  346 2) Be instructed that autoboluses will default to on during normal activity, and off during exercise 347 activity.  348 3) Be reminded again that use of the security PIN on the insulin pump will be required for anyone 349 who is not entirely responsible for their own diabetes care, to include all 2-5 year olds, and those 350 6 years of age or older who may be only partially responsible for their own diabetes management. 351 4) Be instructed that sleep activity will be required during Control-IQ 2.[ADDRESS_72827] of the night. 355 5) Review prior training guidelines from the Control-IQ technology 1.5 training visit, and be taught 356 how the new features are different in Control-IQ technology 2.0. 357 6) Review the study meal late bolus challenges, to be performed twice in each two week period. [ADDRESS_72828]-party 365 components for this purpose. The t:connect mobile app from Tandem Diabetes Care will not be [ADDRESS_72829] glycemic targets are being used. 373 Contacts for the study meal challenges will occur throughout the study Treatment Period. 374 Baseline INSPI[INVESTIGATOR_66680] 8-17, for adult participants age 18+, and [ADDRESS_72830] a phone (or video-conference) follow-up visit at 1 day, 3 days and 1 week, a clinic 378 follow-up visit at 2 weeks, a phone follow-up visit at 3 days and 1 week after switching glycemic targets, 379 and a final clinic visit at 2 weeks after switching glycemic targets, within the windows specified below. 380 TARGET DAY/WEEK VISIT OR PHONE TARGET WINDOW (AROUND TARGET DAY/WEEK) Visit 6: Control-IQ 2.0 Training Visit V 2 weeks (3 days) after Visit 2 Visit 7: 1 days after visit 6 P +12 hours Visit 8: 3 days after visit 6 P +1 day Visit 9: 1 week after visit 6 P +2 days Visit 10: 2 weeks after visit 6 (switch targets) V +3 days Visit 11: 1 day after visit 10 P +12 hours Visit 12: 3 days after visit 10 P +1 days Visit 13: 1 week after visit 10 P +2 days Visit14: 2 weeks after visit 10 V +3 days If necessary, visits should be completed out-of-window rather than missed. A visit is not considered 381 missed until the next visit/phone window opens.  382 The goal will be for all participants to complete all scheduled visits. However, participants who 383 (because of unforeseen circumstances or due to changes in contact [CONTACT_66705] 384 during the evolving COVID-19 pandemic) are unable or unwilling to return for all follow-up visits 385 will be permitted to return for key visits only (Visits 1, 2 and 6) as an alternative to withdrawal from the 386 study. Remote (phone) visits will still be performed as scheduled. When a participant is placed into this [ADDRESS_72831] be obtained prior to conducting the visit 391 remotely: 392 5

 
• Sponsor approval for the reason the visit cannot be performed in person 393 • Investigator approval at the site level for the reason the visit cannot be performed in person 394 In addition, all study procedures listed in section 3.4.1 are to be completed, including upload of the study 395 device and review of the device data. If the final visit is performed remotely, participant will mail in their 396 study devices, and investigators will remotely supervise transition back to their home diabetes treatment 397 plan. 398 3.4.1 Procedures at all Study Visits 399 The following procedures will be performed at each visit, unless otherwise specified: 400 • Review of study device data 401 • Assessment of compliance with study device use by [CONTACT_66706] 402 • Assessment of device issues that have occurred 403 • Assessment of adverse events, using open ended questions to capture hyperglycemic and 404 hypoglycemic events, and their underlying cause and relationship to the study device or other parts of 405 the system (such as the infusion set). 406 • Review of ongoing study late bolus meal challenges when in the treatment period 407 • Baseline INSPI[INVESTIGATOR_66680] 8-17, for adult participants age 18+, 408 and for parents of pediatric participants age 2-17 will be completed at visit 6 409 • Post Assessment INSPI[INVESTIGATOR_66680] 8-17, for adult participants age 410 18+, and for parents of pediatric participants age 2-17 will be completed at visits 10 and 14 411 • SUS Scale will be completed at visits 10 and 14 412 • Study Specific Questionnaire will be completed at visits 10 and 14 413 At the final visit (or at subject withdrawal), the study staff will then supervise the participants transition [ADDRESS_72832] of care therapy as follows: 415 • Study staff will re-evaluate the subject’s baseline therapy doses, noting changes in basal rates, 416 carbohydrate ratios, and correction factors in use at the end of the trial. For prior CSII users, the 417 study investigator will supervise and confirm the entry of settings in the insulin delivery profile of 418 the participant’s home pump at the end of the study. 419 • For those subjects using basal insulin, doses will be adjusted to best match the current daily 420 insulin requirements from CSII use, typi[INVESTIGATOR_897] = (total daily dose + 20%)/2, with further 421 modification as per clinical site usual practice.  422 • Participants must have two CGM or fingerstick BG values, separated by [CONTACT_2669] [ADDRESS_72833] be above 80 mg/dL prior to discharge from the clinic for the final visit. In addition, CGM [ADDRESS_72834] not be going down at the time of discharge. 425 • Study staff will confirm subjects have carbohydrates on hand for their drive back home, and [ADDRESS_72835] insulin delivery profile settings as needed in accordance with their clinical 438 practice. 439 3.8 Early Discontinuation of Study Device 440 If the participant cannot be reached for scheduled study contacts, the participant’s other contact [CONTACT_41528] 441 will be utilized. Participants who are not compliant with the arranged contacts on two separate occasions 442 may be discontinued at the discretion of the investigator. Participants who discontinue the study device 443 prior to the final visit, either by [CONTACT_66707], will be asked to come for an end of 444 study visit and then will be dropped from the study.  445 3.9 Remote Monitoring 446 Real-time CGM alerts will be sent to study staff providers (MD, DO, NP, PA) for the first ten 6-13 year 447 old participants to begin use of the lower target (90-130 mg/dL) for the first week of Control-IQ 2.[ADDRESS_72836] week of use of the lower target, and no safety concerns arise, where: 450 1) No severe hypoglycemia events related to algorithm delivered automated insulin dosing occur 451 that required study staff intervention because the participant was not aware/treating 452 appropriately. 453 2) No severe hyperglycemic events related to algorithm delivered automated insulin dosing 454 occurred that required study staff intervention because the participant was not aware/treating 455 appropriately.  456 In addition, real-time CGM alerts will be sent to study staff providers (MD, DO, NP, PA) for all 2-5 year 457 old participants throughout their use of Control-IQ 2.0 technology (all 4 weeks). 458 
B27

 
Chapter 4: Study Devices and Drugs 459 4.1 Study Devices 460 4.1.1 Insulin Pump 461 For the run in period, participants will use a study provided Tandem t:slim X2 with Control-IQ 1.5 462 technology (Investigational Device). For the treatment period, participants will use a study provided 463 Tandem t:slim X2 with Control-IQ 2.0 technology (Investigational Device). [ADDRESS_72837] once every 10 days. 467 4.1.3 Blood Glucose Meter 468 The study blood glucose meter is the Contour® NEXT (Ascencia Diabetes Care). 469 Blood glucose levels will be measured using the study’s blood glucose meter (glucometer) and the 470 CGM device will be calibrated if needed using the study glucometer and strips in accordance with the 471 manufacturer’s labeling. 472 4.1.4 Ketone Meter 473 The study blood ketone meter is the Precision Xtra Blood Glucose and Ketone Monitoring System 474 (Abbott Diabetes Care). 475 Blood ketone levels will be measured when needed to evaluate prolonged hyperglycemia. The blood 476 glucose meter component of the Precision Xtra device will not be used. 477 4.2 Study Device and Drug Accountability Procedures 478 Device accountability and inventory will be documented to include detailed inventory records of the study 479 CGM supplies, and Tandem insulin pump system. 480 4.3 Participant Access to Study Device at Study Closure 481 Participant will return all investigational study devices and supplies (insulin pump, CGM and related 482 supplies) at study closure. Participant may keep the study ketone meter and study glucometer if these 483 devices are not marked for investigational use only. 484 
B28

 
Chapter 5: Testing Procedures and Questionnaires [ADDRESS_72838] these challenges. This material 492 will be reviewed with each participant, and will be used for source verification for the eCRF database. 493 Before starting each challenge, participants (or parent/guardian if the participant is < 18 years of age) [ADDRESS_72839] assure the participant has a working CGM and Control-IQ is active. For pediatric participants, the 495 participant’s parent or guardian must remain with the child at all times and monitor CGM readings 496 frequently during and through meal completion plus 5 hours (3 hours for participants age 2-5). Snacks [ADDRESS_72840] with study staff no more than 1 day after the completion of each 500 challenge. The participant or parent/guardian must have an on-call phone number for the study team prior 501 to initiation of each challenge. 502 Hyperglycemia and Hypoglycemia treatment guidelines (sections 3.1.3 and 3.1.2) remain in effect for the [ADDRESS_72841] meal of the day (dinner) and participants will be instructed [ADDRESS_72842] 5 hours (3 hours for participants 510 age 2-5) once starting the meal challenge. Participants will be reminded to disable sleep activity if it is 511 inadvertently activated during the challenge, and to re-enable it at the end of the challenge. 512 Time zero (start of the challenge) is at the first bite of food for the study meal. [ADDRESS_72843] of: 515 • Full bolus for the given carbohydrates and calculated correction, given 45 minutes after 516 starting the meal, based on calculated bolus dose using the bolus calculator (with full amount 517 of carbohydrates entered). 518 • Full bolus for the given carbohydrates and calculated correction, given 45 minutes after 519 starting the meal, based on calculated bolus dose using the bolus calculator (with full amount 520 of carbohydrates entered) AND enabling the late bolus feature to 45 minutes later. 521 For each meal challenge, participants will: [ADDRESS_72844] 523 manual insulin bolus more than two hours prior to the meal.   524 B29

 
 2. For participants age 6+, only begin the meal challenge if CGM glucose is between 70 mg/dL and 525 200 mg/dL, and CGM trend arrow is not down.   526 For participants age 2-5, only begin the meal challenge if CGM glucose is between 70 mg/dL and 527 250 mg/dL, and CGM trend arrow is not down.   528 Subjects with hyperglycemia > 200mg/dL will reschedule their challenge for another time. If < 529 70 mg/dL, carbohydrate treatment can be given, after which the meal challenge can continue. [ADDRESS_72845] to complete the meal within 30 minutes of starting to eat. 536 5. Write down the start and end time of eating the meal, as well as the meal content (to include 537 amount of carbohydrate, protein and fat) on the study provided logbook. 538 6. Bolus for the meal 45 minutes after starting to eat, entering the full carbohydrate amount and 539 using the recommended dose from the bolus calculator. For one of the two challenges during a 540 single treatment period, use the bolus calculator but do not change the bolus time. For the other 541 challenge during the same treatment period, use the bolus calculator but change the bolus time to 542 45 minutes late. 543 7. Not give an additional bolus during 5 hours (3 hours for participants age 2-5) after the start of 544 meal challenge (i.e., after start of meal), unless BG is above 300 mg/dL for more than 1 hour, or 545 symptoms of hyperglycemia develop. 546 8. Not take additional carbohydrates during 5 hours (3 hours for participants age 2-5) after the start 547 of meal challenge (i.e., after start of meal), unless BG is < 70 mg/dL, or symptoms of 548 hypoglycemia develop. 549 9. Not exercise for 5 hours (3 hours for participants age 2-5) after the meal challenge begins. 550 10. Make sure sleep activity is not active for the 5 hours (3 hours for participants age 2-5) after the 551 meal challenge begins (start of meal). 552 11. Notify the site within 24 hours after completion of each meal challenge. 553 5.2 Laboratory Testing 554 5.2.1 HbA1c 555 HbA1c measurement will be performed locally at the Screening visit. 556 5.2.2 Urine Pregnancy 557 Urine pregnancy testing performed locally at clinical site for females of child-bearing potential at the 558 screening visit, at the start of study device use (for both device training visits), and anytime pregnancy is 559 suspected. 560 5.2.3 Patient Reported Outcomes 561 The following patient reported outcomes/questionnaires and study specific outcomes will be assessed 562 during the trial as per the study visit schedule. 563 B30

 
INSPI[INVESTIGATOR_66681] 564 The INSPI[INVESTIGATOR_21392] (Insulin Delivery Systems: Perceptions, Ideas, Reflections and Expectations) survey was 565 developed to assess various aspects of a user’s experience regarding automated insulin delivery for both 566 patients and family members. The surveys include various topi[INVESTIGATOR_66682] 1 567 diabetes and their family members based upon >200 hours of qualitative interviews and focus groups. The 568 adult survey includes 31 items; the adolescent survey includes 28 items; and the parent survey includes 30 569 items. Response options for all surveys include a 5-point Likert scale from strongly agree to strongly 570 disagree, along with an N/A option. 571 Administration time is approximately 5 minutes. 572 System Usability Scale (SUS) 573 The System Usability Scale (SUS) is a 10-item questionnaire that measures the overall usability of a 574 system. It is a valid and reliable measure of the perceived usability of a system and is technology-575 agnostic. The questionnaire presents statements with five response options (anchoring the options from 576 strongly disagree to strongly agree) and asks users to rate their agreement to the statements. User scores 577 are transformed into a composite score, from 0 to 100, and this score is taken as an overall measure of the 578 system’s usability; higher scores indicate better perceived usability. [ADDRESS_72846] meals, and general thoughts about the trial.  583 Administration time is approximately 5 minutes. 584 
B31

 
Chapter 6: Unanticipated Problem, Adverse Event, and 585 Device Issue Reporting 586 6.1 Unanticipated Problems 587 Site investigators will promptly report to the Coordinating Center and Sponsor on an eCRF all 588 unanticipated problems meeting the criteria below. For this protocol, an unanticipated problem is an 589 incident, experience, or outcome that meets all of the following criteria: 590 • Unexpected (in terms of nature, severity, or frequency) given (a) the research procedures that are 591 described in the protocol related documents, such as the IRB-approved research protocol and 592 informed consent document; and (b) the characteristics of the subject population being studied 593 • Related or possibly related to participation in the research (possibly related means there is a [ADDRESS_72847] been caused by [CONTACT_941] 595 procedures involved in the research) 596 • Suggests that the research places participants or others at a greater risk of harm than was previously 597 known or recognized (including physical, psychological, economic, or social harm) [ADDRESS_72848] be reported to the study IRB within seven calendar days of 601 recognition. The Sponsor will report to the appropriate regulatory authorities if the IRB determines that 602 the event indeed meets the criteria of an Unanticipated Problem requiring additional reporting. 603 6.2 Adverse Events 604 6.2.1 Definitions 605 Adverse Event (AE): Any untoward medical occurrence (including laboratory findings) associated with 606 study procedures, the use of a device, biologic in a study participant, including any comparator used, 607 irrespective of the relationship between the adverse event and the device(s) under investigation (referred 608 to as Adverse Reaction when caused by a drug). 609 Serious Adverse Event (SAE): Any untoward medical occurrence that meets at least one of the following: 610 • Results in death. 611 • Is life-threatening; (a non-life-threatening event which, had it been more severe, might have become 612 life-threatening, is not necessarily considered a serious adverse event). 613 • Requires inpatient hospi[INVESTIGATOR_1081]. 614 • Results in persistent or significant disability/incapacity or substantial disruption of the ability [ADDRESS_72849] normal life functions (sight threatening). 616 • Is a congenital anomaly or birth defect. 617 • Is considered a significant medical event by [CONTACT_13656] (e.g., may 618 jeopardize the participant or may require medical/surgical intervention to prevent one of the outcomes 619 listed above). [ADDRESS_72850] (UADE): Any serious adverse effect on health or safety or any [ADDRESS_72851], problem, or death 622 was not previously identified in nature, severity, or degree of incidence in the investigational plan or 623 B32

 
application (including a supplementary plan or application), or any other unanticipated serious problem 624 associated with a device that relates to the rights, safety, or welfare of participants (21 CFR 812.3(s)). [ADDRESS_72852] (ADE): Any untoward medical occurrence in a study participant which the device [ADDRESS_72853] contributed (Note that an Adverse Event Form is to be 627 completed in addition to a Device Issues Form, unless excluded from reporting as defined in section 628 6.2.2). 629 Comparator: Medical device, therapy (e.g. active treatment, normal clinical practice), placebo or no 630 treatment, used in the control group in a clinical investigation. (ISO [ZIP_CODE]:2020) 631 Device Complaints and Malfunctions: A device malfunction or complaint is something that happens 632 to a device or related to device performance, whereas an adverse event happens to a participant. A device 633 complaint may occur independently from an AE, or along with an AE. An AE may occur without a 634 device complaint or there may be an AE related to a device complaint. A device malfunction is any 635 failure of a device to meet its performance specifications or otherwise perform as intended. 636 Performance specifications include all claims made in the labeling for the device. The intended 637 performance of a device refers to the intended use for which the device is labeled or marketed. 638 (21 CFR 803.3). Note: for reporting purposes, sites will not be asked to distinguish between device 639 complaints and malfunctions. 640 Use Error: User action or lack of user action while using the medical device (3.34) that leads to a 641 different result than that intended by [CONTACT_3460]. Includes the inability of 642 the user to complete a task. Use errors can result from a mismatch between the characteristics of the user, 643 user interface, task or use environment. Users might be aware or unaware that a use error has occurred. 644 An unexpected physiological response of the patient is not by [CONTACT_3461] a use error. A malfunction 645 of a medical device that causes an unexpected result is not considered a use error. (ISO [ZIP_CODE]:2020) 646 6.2.2 Reportable Adverse Events 647 A reportable adverse event includes all events meeting the definition of an adverse event, except for the 648 following: 649 • Hypoglycemia and hyperglycemia not meeting the criteria below will not be recorded as adverse [ADDRESS_72854] or discontinuation of the study device.  651 • Skin reactions from sensor or pump infusion set placement are only reportable if severe and/or 652 required treatment. 653 
B33

 
All reportable AEs—whether volunteered by [CONTACT_2299], discovered by [CONTACT_66708] [ADDRESS_72855], or other means—will be reported 655 on an AE form online. Each AE form is reviewed by [CONTACT_66709] 656 the coding and the reporting that is required. 657 6.2.3 Hypoglycemic Events 658 Hypoglycemia is only reportable as an adverse event when one of the following criteria is met: 659 • a hypoglycemic event occurred meeting the following definition of severe hypoglycemia: the event 660 required assistance of another person due to altered consciousness, and required another person to 661 actively administer carbohydrate, glucagon, or other resuscitative actions. This means that the 662 participant was impaired cognitively to the point that he/she was unable to treat himself/herself, was 663 unable to verbalize his/ her needs, was incoherent, disoriented, and/or combative, or experienced 664 seizure or loss of consciousness. These epi[INVESTIGATOR_66683] 665 induce seizure or loss of consciousness. If glucose measurements are not available during such an 666 event, neurological recovery attributable to the restoration of glucose to normal is considered 667 sufficient evidence that the event was induced by a low glucose concentration. 668 • evaluation or treatment was obtained at a health care provider facility for an acute event involving 669 hypoglycemia, or the participant contact[CONTACT_66710] 670 an acute event involving hypoglycemia 671 When a severe hypoglycemia event occurs (as defined above), an Adverse Event Form should be [ADDRESS_72856] to 673 reporting requirements. When a severe hypoglycemia event occurs during use of a study device, it 674 generally will be considered to be unrelated to the device (per section 6.2.5) if the device functioned as 675 intended and there does not appear to be a flaw in how the device is intended to function. 676 6.2.4 Hyperglycemic/Ketotic Events 677 Hyperglycemia is only reportable as an adverse event when one of the following criteria is met:   678 • the event involved DKA, as defined by [CONTACT_3467] (DCCT) and 679 described below 680 • evaluation or treatment was obtained at a health care provider facility for an acute event involving 681 hyperglycemia or ketosis, or the participant contact[CONTACT_66711] 682 manage the hyperglycemia/ketosis 683 • blood ketone level ≥1.0 mmol/L, even if there was no communication with a health care provider at [ADDRESS_72857] 686 been present based on available data: 687 • Symptoms such as polyuria, polydipsia, nausea, or vomiting; 688 • Serum ketones >1.5 mmol/L or large/moderate urine ketones; 689 • Either arterial blood pH <7.30 or venous pH <7.24 or serum bicarbonate (or CO2) <15; and 690 • Treatment provided in a health care facility 691 When a hyperglycemia/ketotic event qualifies as an AE, or as a SAE as defined in section 6.2.1, an [ADDRESS_72858] to reporting requirements. Hyperglycemia events not meeting criteria 694 B34

 
 for DKA generally will not be considered as serious adverse events unless one of the SAE criteria in 695 section 6.2.1 is met. 696 When a hyperglycemia/DKA event occurs during use of a study device, it generally will be considered to 697 be unrelated to the device (per section 6.2.5) if the device functioned as intended and there does not 698 appear to be a flaw in how the device is intended to function. 699 6.2.5 Relationship of Adverse Event to Study Investigational Device 700 The study investigator will assess the relationship of any adverse event to the study device or study drug. 701 The Medical Monitor also will make this assessment, which may or may not agree with that of the study 702 investigator. Reporting requirements will be based on the Medical Monitor’s assessment. 703 To ensure consistency of adverse event causality assessments, investigators should apply the following 704 general guidelines when determining whether an adverse event is related to a study device or study drug: 705 Unrelated: The AE is clearly not related to a study drug/device and a likely alternative etiology exists 706 such as an underlying disease, environmental or toxic factors or other therapy. 707 Unlikely Related: The AE does not follow a reasonable temporal sequence during or after use of study 708 drug/device and a more likely alternative etiology exists such as an underlying disease, environmental or 709 toxic factors, or other therapy.  710 Possibly Related: The AE occurred in a reasonable time during or after use of study drug/device; but 711 could be related to another factor such as an underlying disease, environmental or toxic factors, or other 712 therapy; and there is a possible, though weak, scientific basis for establishing a causal association 713 between the AE and the study drug/device. 714 Probably Related: The AE occurred in a reasonable time during or after use of study drug/device; is 715 unlikely to be related to another factor such as an underlying disease, environmental or toxic factors, or 716 other therapy; and there is a plausible, though not strong, scientific basis for establishing a causal 717 association between the AE and the study drug/device.  718 Definitely Related: The AE occurred in a reasonable time during or after use of study drug/device; 719 cannot be explained by [CONTACT_3468], environmental or toxic factors, or 720 therapy; and there is a strong scientific basis for establishing a causal association between the AE and the 721 study drug/device.  722 Events determined to be Possibly Related, Probably Related, or Definitely Related will be considered 723 ‘Related’ with respect to any required IRB and FDA reporting. 724 6.2.6 Severity (Intensity) of Adverse Events 725 The severity (intensity) of an adverse event will be rated on a three-point scale: (1) mild, (2) moderate, 726 or (3) severe. A severity assessment is a clinical determination of the intensity of an event. Thus, a severe 727 adverse event is not necessarily serious. For example, itching for several days may be rated as severe, but 728 may not be clinically serious. 729 MILD: Usually transient, requires no special treatment, and does not interfere with the participant’s daily 730 activities. 731 MODERATE: Usually causes a low level of inconvenience, discomfort or concern to the participant 732 and may interfere with daily activities, but is usually ameliorated by [CONTACT_66712] 733 participant is able to continue in study. 734 SEVERE: Interrupts a participant’s usual daily activities, causes severe discomfort, may cause 735 discontinuation of study device, and generally requires systemic drug therapy or other treatment. 736 B35

 
 6.2.7 Expectedness 737 For a serious adverse event that is considered possibly related to study device, the Medical Monitor will 738 classify the event as unexpected if the nature, severity, or frequency of the event is not consistent with the 739 risk information previously described in the protocol, labeling, or Investigator Brochure. 740 6.2.8 Coding of Adverse Events 741 Adverse events will be coded using the MedDRA dictionary. 742 6.2.9 Outcome of Adverse Events 743 The outcome of each reportable adverse event will be classified by [CONTACT_3470]: 744 • RECOVERED/RESOLVED – The participant recovered from the AE/SAE without sequelae. Record 745 the AE/SAE stop date. 746 • RECOVERED/RESOLVED WITH SEQUELAE – The event persisted and had stabilized without [ADDRESS_72859] the AE/SAE stop date. 748 • FATAL – A fatal outcome is defined as the SAE that resulted in death. Only the event that was the 749 cause of death should be reported as fatal. AEs/SAEs that were ongoing at the time of death; 750 however, were not the cause of death, will be recorded as “resolved” at the time of death. 751 • NOT RECOVERED/NOT RESOLVED (ONGOING) – An ongoing AE/SAE is defined as the event 752 was ongoing with an undetermined outcome. 753 An ongoing outcome will require follow-up by [CONTACT_66713] 754 of the AE/SAE. The outcome of an ongoing event at the time of death that was not the cause of 755 death, will be updated and recorded as “resolved” with the date of death recorded as the stop 756 date. 757 • UNKNOWN – An unknown outcome is defined as an inability to access the participant or the 758 participant’s records to determine the outcome (for example, a participant that was lost to follow-up). 759 If any reported adverse events are ongoing when a participant completes the study (or withdraws), [ADDRESS_72860] of improvement or change, even after the participant has completed all 762 applicable study visits/contacts. For all other adverse events, data collection will end at the time the 763 participant completes the study. Note: participants should continue to receive appropriate medical care 764 for an adverse event after their participation in the study ends. 765 6.3 Reportable Device Issues 766 All UADEs and ADEs as defined in section 6.2.1 will be reported as both ‘device issues’ and adverse [ADDRESS_72861] not been met: 771 • CGM sensor lasting fewer days than expected per manufacturer 772 • CGM tape adherence issues 773 • Pump infusion set insertion lasting fewer days than expected per manufacturer 774 • Battery lifespan deficiency due to inadequate charging or extensive wireless communication 775 B36

 
• Intermittent device component disconnections/communication failures not requiring system 776 replacement or workaround/resolution not specified in user guide/manual. 777 • Device issues clearly addressed in the user guide manual that do not require additional [ADDRESS_72862] be reported 781 by [CONTACT_66714] 1 working day of the site becoming aware of the event. This can occur 782 via phone or email, or by [CONTACT_66715]. If the form(s) are not 783 initially completed, they should be competed as soon as possible after there is sufficient information to 784 evaluate the event. All other reportable ADEs and other reportable AEs should be submitted by 785 completion on the eCRF(s) within 7 days of the site becoming aware of the event.  786 The Sponsor will notify all participating investigators of any adverse event that is serious, related, and 787 unexpected. Notification will be made within 10 working days after the Sponsor becomes aware of the 788 event. 789 Each principal investigator [INVESTIGATOR_3411]-related adverse events and abiding 790 by [CONTACT_66716]/her Institutional Review Board or Ethics Committee.  791 Upon receipt of a qualifying event, the Sponsor will investigate the event to determine if a UADE has 792 occurred, and if indicated, report the results of the investigation to all overseeing IRBs, and the FDA 793 within 10 working days of the Sponsor becoming aware of the UADE per 21CFR 812.46(b). The Sponsor [ADDRESS_72863] led to a UADE, including device complaints and malfunctions, irrespective 800 of whether an adverse event occurred. 801 6.5 Safety Oversight 802 The study Sponsor’s Medical Director will serve as Medical Monitor, and will review all reported adverse 803 events, including all cases of severe hypoglycemia and DKA, and adverse device effects that are reported 804 during the study. SAEs typi[INVESTIGATOR_66684] 1 working day of reporting. Other AEs typi[INVESTIGATOR_897] 805 will be reviewed on a weekly basis.  806 The Medical Monitor will determine if the events require expedited reporting to FDA, IRB and/or all 807 participating sites. In addition, the Medical Monitor will confirm the MedDRA code assigned and 808 adjudicate events as specified in the safety management plan for relatedness to the study procedure and 809 investigational device, assess seriousness and severity, and determine if the event the event is anticipated 810 or unanticipated. Both the investigator’s and Medical Monitor’s assessments will be recorded, however, 811 the adjudication decision of the Medical Monitor will be used for the final classification of events, 812 including relatedness to the study procedures and/or the investigational device, for the determination of [ADDRESS_72864] labeling, and publications or presentations. 814 
B37

 
 6.6 Stoppi[INVESTIGATOR_2121] 815 6.6.1 Participant Discontinuation of Study Device 816 In the case of an unanticipated system malfunction resulting in a severe hypoglycemia or DKA event 817 (or a malfunction that could have led to severe hypoglycemia or DKA), use of the study device will be 818 suspended for that participant while the problem is diagnosed. The UADE will be reported to the IRB and 819 FDA. After assessment of the problem and any correction, use of the study device will not be restarted 820 until approval is received from the IRB and FDA. 821 In the absence of a device malfunction, use of the study device by a participant will be discontinued if 822 any of the following occur:  823 • The investigator believes it is unsafe for the participant to continue on the intervention. This could be 824 due to the development of a new medical condition or worsening of an existing condition; or 825 participant behavior contrary to the indications for use of the device that imposes on the participant’s 826 safety 827 • The participant requests that the treatment be stopped 828 • Participant pregnancy 829 • One distinct epi[INVESTIGATOR_66685] 6.2.4 830 • One distinct severe hypoglycemia events in the study treatment period as defined in section 6.2.[ADDRESS_72865] to 832 determination of cause and whether the occurrence of the event can be attributed to use of the study 833 device or study drug.  834 6.6.2 Criteria for Suspending or Stoppi[INVESTIGATOR_3396] 835 In addition to the suspension of device use due to a UADE as described in section 6.6.1, study activities 836 could be similarly suspended if the manufacturer of any constituent study device requires stoppage of 837 device use for safety reasons (e.g. product recall). The affected study activities may resume if the [ADDRESS_72866] initiated Control-IQ 842 technology 2.0 use. The IRBs and FDA will be notified. After assessment of the problem and any 843 corrections are implemented, use of the closed-loop system may be restarted if approval is received from 844 the IRBs and FDA. 845  846 
B38

 
Chapter 7: Miscellaneous Considerations 847 7.1 Drugs Used as Part of the Protocol 848 Subjects will use their own Humalog (insulin lispro) or Novolog (insulin aspart) during the Run In and 849 Treatment Period with the study devices. 850 7.2 Collection of Medical Conditions and Medications 851 Pre-Existing Conditions: Any medical condition that is either present at screening, a chronic disease, [ADDRESS_72867] the participant’s health during the course of the study (e.g., prior 853 myocardial infarction or stroke) will be recorded. 854 Medical Conditions Developi[INVESTIGATOR_66686]: Medical conditions developi[INVESTIGATOR_66687] 855 be reviewed by [CONTACT_66717]. 856 Medications: All medications in use at the time of screening or added during the course of the study will 857 be recorded. Nutraceuticals and preventative treatment also will be recorded. Medications only taken as 858 needed either can be recorded when prescribed or only recorded if used during the study. Glucagon for 859 treatment of severe hypoglycemia will only be recorded if used during the study. 860 7.3 Prohibited Medications, Devices, Treatments, and Procedures 861 Treatment with any insulin other than Humalog or Novolog insulin with the study pumps is not permitted. 862 Treatment with a non-insulin glucose -lowering agent, other than metformin, is not permitted, including 863 GLP-1 agonists, Symlin, DPP-4 inhibitors, SGLT-2 inhibitors, sulfonylureas. 864 The investigational study devices (t:slim X2 insulin pump with Control-IQ technology 1.5 or 2.0) and 865 study sensor and transmitter (Dexcom CGM sensor and transmitter) must be removed before magnetic 866 resonance imaging (MRI), computed tomography (CT) or diathermy treatment. Participants may continue [ADDRESS_72868] a glucagon preparation for rescue therapy for severe 870 hypoglycemia. 871 7.5 Pregnancy Reporting 872 If pregnancy occurs, the participant will be discontinued from the study. The occurrence of pregnancy 873 will be reported to the Coordinating Center within seven days and to the IRB as an Unanticipated 874 Problem within seven calendar days. 875 7.6 Participant Compensation 876 Participant compensation will be specified in the informed consent form. 877 7.7 Participant Withdrawal 878 Participation in the study is voluntary, and a participant may withdraw at any time. For participants who 879 withdraw, their data will be used up until the time of withdrawal. 880  881 
B39

 
 Chapter 8: Statistical Considerations [ADDRESS_72869] parametric techniques are found to be 885 inadequate, an appropriate non-parametric technique will be used. Categorical variables will be presented 886 using frequencies and percentages and compared using differences in proportions unless stated otherwise. 887 For safety/adverse event reporting, both the number of overall events and the number of subjects 888 experiencing that event will be tabulated. No corrections will be made for multiple testing procedures. All 889 analyses will be conducted using SAS® version 9.[ADDRESS_72870] 30 adults and adolescents age 14+ years old, [ADDRESS_72871] completing 2 weeks 905 of Control-IQ 1.5 technology use, 2 weeks of Control-IQ 2.0 technology use with the target of 112.5 to 906 160 mg/dL, and 2 weeks of Control-IQ 2.0 technology use with the target of 90-130 mg/dL. The choice of [ADDRESS_72872] an HbA1c at 910 baseline of ≥ 7.5%, and have at least 6 participants age 14-17. 911 8.4 Outcome Measures 912 Primary Endpoints 913 1. Severe hypoglycemia (with cognitive impairment such that assistance of another individual is needed 914 for treatment) during study compared with data on severe hypoglycemic events reported by T1D 915 Exchange clinic registry over a 3-month time period 916 2. Diabetic ketoacidosis during study compared with data on DKA events  917 3. Number of unanticipated adverse device effects 918 4. Number of other serious device-related adverse events 919 Secondary Endpoints  920 1. All device-related adverse events 921 B40

 
 2. CGM hypoglycemia outcomes, compared between the three study time periods 922 a. Overall % time <54 mg/dL 923 b. Overall % time <70 mg/dL 924 3. Times in ranges-overall (70-180 mg/dL, >180 mg/dL, >250 mg/dL, 70-140 mg/dL) compared 925 between the three study time periods 926 4. Mean glucose compared between the three study time periods. 927 5. Overall variability (CV and SD) compared between the three study time periods 928 6. Secondary endpoints 2 - 5 compared during daytime and nighttime, across the three study time 929 periods 930 7. Secondary endpoints 2 - 5 as well as adverse events, during the study meal challenge periods, for 931 late bolus feature use compared to normal bolus in the meal challenges. 932 8. Time to intervention for hypo- or hyperglycemia during the study meal challenge periods, for late 933 bolus feature use compared to normal bolus in the meal challenges. 934 9. Number of interventions for hypo- or hyperglycemia during the study meal challenge periods for 935 late bolus feature use compared to normal bolus in the meal challenges. 936 10. Subgroup Analysis for all metrics by [CONTACT_50802], baseline HbA1c cohort (HbA1c at baseline of ≥ 937 7.5%, yes/no), and target activity use (standard target, lower target, sleep activity, exercise 938 activity). 939  940 8.5 Analysis Datasets  941 Safety analysis set: All participants who initiate the Treatment Period and use the study device at least 942 one time (including training).  943 CGM analysis set: Any member of the Safety Analysis Set who has at least 24 hours of CGM data during 944 either Treatment Period. CGM data occurring within the meal challenge windows (from time of start of 945 meal up to 5 hours afterwards [3 hours for age 2-5]) will not be used to determine whether a subject is 946 included in CGM analysis set or not. 947 Late bolus meal challenge set: Any member of the Safety Analysis Set who has at least [ADDRESS_72873] one meal 949 challenge. 950 8.6 Analysis of Endpoints 951 8.6.1 Analysis of the Safety Event Endpoints 952 Safety events (not including CGM defined events defined in sections 6.2.2, 6.2.3, and 6.2.4) will be based 953 on Safety analysis set, and tabulated for each primary endpoint as the number of events per participant, 954 the number of participants with ≥ 1 event, and the rate of events per 100 person-years. A 95% confidence 955 interval will be calculated for the rate of events per 100 person-years. 956 Since study eligibility excluded participants with 2 or more severe hypoglycemia or DKA events in the 957 prior 6 months, an unbiased comparison of the event rate during the Treatment Period with the pre-study 958 event rate is not possible. Therefore, the severe hypoglycemia and DKA event rates will be compared 959 with the T1D Exchange data,4 which reported the frequency of 1 or more severe hypoglycemia and DKA 960 events in the prior 3 months. The proportion of participants with events during the Treatment Period (each 961 B41

 
period separately) will be compared with the run-in period as well as with the T1D Exchange frequency. 962 Differences in proportions across the three study periods (two active treatments and the run in) will be [ADDRESS_72874] over 24 hours, during daytime (6am-978 11:59pm), and during nighttime (12am-5:59am), as well as by [CONTACT_50802] (adults/adolescents, children 6 – 979 13, and preschool), baseline HbA1c cohort (HbA1c at baseline of ≥ 7.5%,yes/no), and target activity use 980 as specified by [CONTACT_8121] (standard target, lower target, sleep activity, and exercise activity). 981 The main statistical comparison will be made between the three 2-week periods (Run In, Treatment [ADDRESS_72875] target, Treatment Period at lower target). The comparison will be pairwise – Run-in vs [ADDRESS_72876] vs lower target. The percent time in glycemic ranges 984 will be calculated as the number of measurements in the specified range divided by [CONTACT_66718] 985 measurements for which it can be determined whether or not the measurement was in specified range. 986 The “Low” and “High” CGM readings will be included in all analyses. Percent time will be compared [ADDRESS_72877] assuming sufficient normality assumptions hold, otherwise an appropriate non-988 parametric method will be utilized.  989 8.6.4 Analysis of Late Bolus Meal Challenges 990 All analyses in section 8.6.4 will be conducted in the late bolus meal challenge analysis set. Data included 991 in these analyses will be restricted to data during the meal challenge window (start of meal through 5 992 hours from meal imitation [3 hours for age 2-5]). The subgroups assessed will be the same as sections 993 8.6.1 – 8.6.3 (age cohort, baseline HbA1c cohort (HbA1c at baseline of ≥ 7.5%. yes/no), etc.) 994 [IP_ADDRESS] Late Bolus Meal Challenge Safety and CGM Subgroup Analysis 995 Two challenges are expected per subjects per treatment period for a total of four challenges, therefore 996 agreement of outcomes will need to be assessed. For continuous outcomes, two sets of Pearson’s 997 correlation coefficients will be calculated to measure concordance: one restricted to each treatment period 998 (higher range target and lower range target), and a single coefficient for all four challenges. For 999 categorical outcomes, a Cohen’s kappa statistic for agreement or a similarly appropriate statistic will be 1000 calculated and presented to describe agreement/dependence of outcomes by [CONTACT_66719]. Results [ADDRESS_72878] non-independence (i.e. [ADDRESS_72879] per study period).  1006 [IP_ADDRESS]  Time to Intervention Analysis 1007 Time to intervention for both hypo- or hyperglycemia during the study meal challenge periods will be 1008 summarized. Time to intervention is defined as the time (in minutes) from start of meal until the first [ADDRESS_72880] to time to intervention. Results will be 1016 compared by [CONTACT_66720]. 1017 [IP_ADDRESS] Number of interventions analysis 1018 Number of interventions for hypo- or hyperglycemia during the study meal challenge periods will be 1019 summarized both overall and by [CONTACT_24975]. The results will be presented using general summary statistics. 1020 Type of intervention may include timing of intervention (during meal, less than one hour after starting 1021 meal, greater than one hour after meal start), the number of carbs administered (grouped in increments of 1022 10 grams), and the timing of carb administration (less than 15 minutes per administration vs 15 minutes 1023 or more). The categories and groupi[INVESTIGATOR_66688] 1024 on the types of interventions that actually occur in the study. Results will be compared by [CONTACT_3148] 1025 period and across treatment periods. 1026 Type of intervention will be reviewed and assessed by [CONTACT_66721] 1027 define the logic that can be applied across all subjects (e.g., an intervention that occurred more than 15 1028 minutes after the previous intervention will count as new intervention). Different logic may be applied to 1029 different age cohorts. This logic will be fully detailed in the final clinical study report.  1030 8.7 Intervention Adherence 1031 The following tabulations will be performed: 1032 • Sensor use – percent time of use as a function of overall treatment period 1033 • Sensor use is defined as percent of time CGM is recorded as active (to include warmup) vs total 1034 study time. 1035 • Closed loop system use – percent time of use as a function of overall treatment period 1036 • Closed loop system use is defined as percent of time closed-loop is recorded as active (to include 1037 pi[INVESTIGATOR_66689]) vs total study time. 1038 • Percent time in different operational modes as a function of overall treatment period 1039 • The investigational device allows for the following operational modes: standard target, lower 1040 target, sleep activity, and exercise activity. 1041 For intervention adherence, overall treatment period is calculated from the start of the treatment period to 1042 the end of the treatment period where any gaps in CGM data are ignored.  1043 
B43

 
1 8.8 Protocol Adherence and Retention 1044 The following tabulations and analyses will be performed to assess protocol adherence for the study: 1045 • Number of protocol deviations by [CONTACT_66722], and number of unique subjects with each type of 1046 protocol deviation  1047 • Disposition summary (e.g., chart, table) accounting for all enrolled participants at each scheduled visit 1048 • Number of and reasons for unscheduled visits and phone calls 1049 • Number of participants who were enrolled but did not enter the Treatment Period and reasons 1050 • Number of participants who stopped treatment and reasons 1051 8.9 Baseline Descriptive Statistics 1052 Baseline demographic and clinical characteristics of the cohort of participants who initiate the Treatment 1053 Period will be summarized in a table using summary statistics appropriate to the distribution of each 1054 variable. Descriptive statistics will be displayed by [CONTACT_66723]: 1055 • Age 1056 • Sex 1057 • Race 1058 • Ethnicity 1059 • Socio-economic factors (income, education, and/or insurance status) 1060 • Diabetes duration 1061 • HbA1c 1062 • BMI 1063 • Total daily insulin 1064 • Prior severe hypoglycemia and DKA events in the last 6 months 1065 8.10 Additional Tabulations and Analyses 1066 The following data will be tabulated at baseline, for the run-in period, and for the two treatment periods. 1067 • Insulin metrics (units/kg): total daily insulin, total daily basal insulin, total daily bolus insulin (plus 1068 total daily manual bolus, total daily automated bolus) [ADDRESS_72881] to device issues: 1071 • Number of device issues by [CONTACT_24975], and number of unique subjects with each type of device issue 1072 8.12 Planned Interim Analyses 1073 No formal interim analyses are planned. 1074 
B44

 
1 8.13 Subgroup Analyses 1075 Results will be tabulated according to age cohort, baseline HbA1c category, and target activity use 1076 (standard target, lower target, sleep activity, exercise activity). There is an enrollment goal of at least half [ADDRESS_72882] an HbA1c at baseline of ≥ 7.5%, and all participants meeting 1078 that criteria will be analyzed as a subgroup. 1079 8.14 Multiple Comparison/Multiplicity 1080 There are no adjustments performed for multiple comparisons.  1081 8.15 Handling of Missing Data 1082 All practical monitoring and follow-up steps will be taken to ensure complete and accurate data 1083 collection. All analyses will be based on available data only; no imputation for missing data is planned.  [ADDRESS_72883] deviation, and range. 95% confidence intervals, and/or first and third quartile may be presented 1090 were appropriate. Categorical variables will be summarized using count and percent of each level of 1091 categorical variable. Any statistical testing will be performed at a two-sided significance level of 5% with 1092 no adjustment for multiple testing. If the observed data are found not to follow a normal distribution, non-1093 parametric methods may be employed (such as Wilcoxon rank sum test as appropriate).  1094 The statistical software package SAS® 9.3 or later will be used for all data derivations, summaries, 1095 listings, and statistical analyses. Additional statistical software may be used for graphics or validation 1096 purposes as appropriate.1097 
B45

 
Chapter 9: Data Collection and Monitoring 1098 9.1 Case Report Forms and Other Data Collection 1099 The main study data are collected on electronic case report forms (eCRFs). When data are directly 1100 collected in electronic case report forms, this will be considered the source data. For any data points 1101 for which the eCRF is not considered source (e.g. lab results that are transcribed from a printed report [ADDRESS_72884], study specific source worksheets, etc.), the 1103 original source documentation will be maintained in the participant’s study chart or medical record. This [ADDRESS_72885]. These documents should be retained for a longer period, however, 1115 if required by [CONTACT_427]. No records will be destroyed without the written consent of the sponsor, 1116 if applicable. It is the responsibility of the sponsor to inform the investigator when these documents no 1117 longer need to be retained. 1118 9.3 Quality Assurance and Monitoring 1119 Designated personnel from the Coordinating Center will be responsible for maintaining quality 1120 assurance (QA) and QC systems to ensure that the clinical portion of the trial is conducted and data are [ADDRESS_72886] 1126 and monitoring will conform with 21 Code of Federal Regulations (CFR) 812. This plan will describe in [ADDRESS_72887] importance for monitoring at the site are participant eligibility and adverse events. 1130 Therefore, the monitoring plan will focus on these areas. As much as possible, remote monitoring will be 1131 performed in real-time with on-site monitoring performed to evaluate the verity and completeness of 1132 the key site data. Elements of the monitoring may include: 1133 
B46

 
• Qualification assessment, training, and certification for sites and site personnel 1134 • Oversight of Institutional Review Board (IRB) coverage and informed consent procedures 1135 • Central (remote) data monitoring: validation of data entry, data edits/audit trail, protocol review of 1136 entered data and edits, statistical monitoring, study closeout 1137 • On-site monitoring (site visits): source data verification, site visit report 1138 • Agent/Device accountability 1139 • Communications with site staff 1140 • Patient retention and visit completion 1141 • Quality control reports 1142 • Management of noncompliance 1143 • Documenting monitoring activities 1144 • Adverse event reporting and monitoring [ADDRESS_72888] access to all trial related source data/documents, and reports 1149 for the purpose of monitoring and auditing by [CONTACT_456], and inspection by [CONTACT_66724] 1150 authorities. 1151 9.4 Protocol Deviations 1152 A protocol deviation is any noncompliance with the clinical trial protocol, GCP, or procedure 1153 requirements. The noncompliance may be either on the part of the participant, the investigator, or the 1154 study site staff. A significant (or major) deviation is any deviation that departs from the established [ADDRESS_72889] that it poses an increase in the risk to subjects, adversely affects the welfare, 1156 rights, or safety of the research subjects, or negatively influences the scientific study integrity. As a 1157 result of a significant deviation, a corrective and preventive action plan shall be developed by [CONTACT_779] 1158 and implemented promptly. 1159 The site PI/study staff is responsible for knowing and adhering to their IRB requirements. Further details 1160 about the handling of protocol deviations will be included in the monitoring plan. 1161  1162 
B47

 
Chapter 10: Ethics/Protection of Human Participants [ADDRESS_72890] 1164 The investigator will ensure that this study is conducted in full conformity with Regulations for the 1165 Protection of Human Participants of Research codified in 45 CFR Part 46, 21 CFR Part 50, 21 CFR 1166 Part 56, and/or the ICH E6. 1167 10.2 Institutional Review Boards 1168 The protocol, informed consent form(s), recruitment materials, and all participant materials will be [ADDRESS_72891] 1170 be obtained before any participant is enrolled. Any amendment to the protocol will require review and 1171 approval by [CONTACT_3484]. All changes to the consent form 1172 will be IRB approved; a determination will be made regarding whether previously consented participants 1173 need to be re-consented. 1174 10.3 Informed Consent Process 1175 10.3.1 Consent Procedures and Documentation 1176 Informed consent is a process that is initiated prior to the individual’s agreeing to participate in the study 1177 and continues throughout the individual’s study participation. Extensive discussion of risks and possible [ADDRESS_72892] by [CONTACT_3486], their staff, and the 1193 sponsor(s) and their agents. This confidentiality is extended to cover testing of biological samples and [ADDRESS_72893] all documents and records required to be 1200 maintained by [CONTACT_093], including but not limited to, medical records (office, clinic, or hospi[INVESTIGATOR_307]) 1201 and pharmacy records for the participants in this study. The clinical study site will permit access to such 1202 records. 1203 
B48

 
The study participant’s contact [CONTACT_66725] 1204 during the study. At the end of the study, all records will continue to be kept in a secure location for as 1205 long a period as dictated by [CONTACT_3488], institutional policies, sponsor requirements, and 1206 applicable regulations. 1207 Study participant research data, which is for purposes of statistical analysis and scientific reporting, will 1208 be transmitted to and stored at the Coordinating Center. This will not include the participant’s contact [INVESTIGATOR_1660] [ADDRESS_72894] protected. At the end of the study, all study databases will be de-1213 identified and archived at the Coordinating Center. 1214 10.3.3 Future Use of Stored Specimens and Data 1215 Data collected for this study will be analyzed and stored at the Coordinating Center. After the study is 1216 completed, a dataset will be provided to the study Sponsor. 1217 No biologic specimens will be stored. 1218  1219 
B49

 
Chapter 11: References [ADDRESS_72895], Anderson SM, Church MM, 1223 Dadlani V, Ekhlaspour L, Forlenza GP, Isganaitis E, Lam DW, Kollman C, Beck RW; iDCL 1224 Trial Research Group.  Six-month randomized, multicenter trial of closed-loop control in 1225 type 1 diabetes. N Engl J Med. 2019; 381:1707-1717. [ADDRESS_72896] E, Carria L, Emory E, Hsu LJ, Oliveri M, Kollman CC, Dokken BB, 1228 Weinzimer SA, DeBoer MD, Buckingham BA, Cherñavvsky D, Wadwa RP; iDCL Trial 1229 Research Group. A randomized trial of closed-loop control in children with type 1 diabetes. 1230 N Engl J Med. 2020; 383:836-845. 1231 3. Breton M, Kovatchev B. One year real-world use of the Control-IQ advanced hybrid closed 1232 loop technology. Diabetes Technol Ther. 2021;23:601-608. 1233 4. Foster et al. State of type 1 diabetes management and outcomes from the T1D Exchange in 1234 2016-2018. Diabetes Technol Ther. 2019; 21:66-72. 1235  1236 
B50
